Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study

Purpose The aim of this study was to investigate whether an early, accurate identification of disease using 18 F-DCFPyL PET/CT imaging resulted in a change of decision on treatment management, for individual patients with biochemically recurrent (BCR), hormone-sensitive prostate cancer. Methods In t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2021-08, Vol.48 (9), p.2960-2969
Main Authors: Meijer, Dennie, van Leeuwen, Pim J., Oosterholt, Pepijn M. J., Bodar, Yves J. L., van der Poel, Henk G., Hendrikse, N. Harry, Donswijk, Maarten L., Wondergem, Maurits, Vellekoop, Annelies E., van Moorselaar, R. Jeroen A., Nieuwenhuijzen, Jakko A., Oprea-Lager, Daniela E., Vis, André N.
Format: Article
Language:English
Subjects:
Biochemistry
Cancer surgery
Cancer therapies
Cardiology
Computed tomography
Disease management
Fluorine isotopes
Imaging
Lymph nodes
Lymphatic system
Medicine
Medicine & Public Health
Nuclear Medicine
Oncology
Oncology – Genitourinary
Original
Original Article
Orthopedics
Patients
Positron emission
Prostate cancer
Prostatectomy
Radiation therapy
Radiology
Robotic surgery
Tomography
Urological surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The aim of this study was to investigate whether an early, accurate identification of disease using 18 F-DCFPyL PET/CT imaging resulted in a change of decision on treatment management, for individual patients with biochemically recurrent (BCR), hormone-sensitive prostate cancer. Methods In this retrospective study, a total of 253 patients with BCR who underwent restaging 18 F-DCFPyL PET/CT were assessed. Two urologists specialized in uro-oncology were asked to formulate a preferred treatment for each patient before and after knowing the results of the 18 F-DCFPyL PET/CT. Results Out of 253 patients, 191 (75%) underwent robot-assisted radical prostatectomy (RARP) as primary therapy, and 62 (25%) external beam radiation therapy (EBRT). In 103/253 cases (40.7%), a preferred treatment change based on the 18 F-DCFPyL PET/CT findings was reported. In patients post-RARP, a positive 18 F-DCFPyL PET/CT (OR 6.21; 95%CI 2.78–13.8; p  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-021-05222-5